Norman Stockbridge is appointed permanent director of the Center for Drug Evaluation & Research's Division of Cardiovascular and Renal Products. Stockbridge has been serving as acting director since Douglas Throckmorton became CDER deputy director in May 2004 (1"The Pink Sheet" April 19, 2004, p. 4). Stockbridge joined FDA in 1991 as a medical officer and was appointed Cardio-Renal division deputy director in 2002...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
Kwabena Frimpong-Manso Opuni has been appointed as the new acting CEO of the Ghana Food and Drugs Authority, succeeding Delese Darko, who is now head of the Africa’s pan-continental medicines agency.
The European Commission has published two new strategies on stockpiling that will improve the availability of critical medicines in times of crisis and reduce the EU’s dependance on suppliers outside the bloc.